drugset / Trial / NCT06054425
A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults
RandomizedParallel-groupOpen-labelBasic science
Summary
The objective of this study is to assess the bioavailability of risankizumab liquid vial manufactured with the new process (CMC3) relative to the current process (CMC2).
Timeline
- Start
- 2023-11-20
- Primary completion
- 2024-05-06
- Completion
- 2024-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risankizumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.